Clinical Trials | May 20, 2024
Bristol Myers Squibb’s CAR T Cell Therapy Breyanzi approved by USFDA
95.7% of patients responded to Breyanzi in the TRANSCEND FL trial
95.7% of patients responded to Breyanzi in the TRANSCEND FL trial
Pfizer to discuss regulatory submission with FDA, potentially leading to eighth indication for ADCETRIS
Highlighting fully integrated organization, robust portfolio, and strategic priorities to drive long-term sustainable growth
Pelabresib recently met its primary endpoint of spleen volume reduction and demonstrated favorable trends in symptom improvement
NexCAR19 is an indigenously developed CD19 targeted CAR-T cell therapy
Phase 2 study to assess efficacy and safety of once daily linperlisib in patients with advanced peripheral T/NK cell lymphoma
Company creates Younger T Cells for fighting cancer using its NR2F6 technology
Yescarta is First CAR T-cell therapy to receive NCCN treatment guideline category 1 recommendation --
The interim data combines three mRNAs into one therapy injected directly into the tumour
The product will be available in 500 mg/2.5 mL and 1 g/5 mL vials
Subscribe To Our Newsletter & Stay Updated
